Who published this market news?

TradingView published this market news item.

LB Pharmaceuticals accelerates Phase 3 NOVA-2 topline to H1 2027, pre-NDA meeting planned

LB Pharmaceuticals announced accelerated topline results timing for the Phase 3 NOVA-2 trial of LB-102, now expected in the first half of 2027.Key Highlights:Original SEC Filing: LB PHARMACEUTICALS INC [ LBRX ] - 8-K - Jul. 22, 2026This is an AI-powered summary. It may contain inaccuracies. Conside…

LB Pharmaceuticals announced accelerated topline results timing for the Phase 3 NOVA-2 trial of LB-102, now expected in the first half of 2027.

Key Highlights:

Now expects topline results from pivotal Phase 3 NOVA-2 in H1 2027 due to faster-than-expected enrollment.
Plans to schedule a pre-NDA meeting with the FDA in the second half of 2027 following topline results.
NOVA-2 is a randomized, double-blind, placebo-controlled trial enrolling ~460 patients across 25 U.S. sites.
Company states cash runway expected to fund operations into Q2 2029, supporting multiple clinical readouts.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.